Oxford Immunotec Announces Launch of the Accutix(TM) Brand
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the Accutix brand for its tick-borne disease offering.
"Incorporating the feedback of our customers was a key consideration in our selection of a new brand name," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Tick-borne disease specialists value the accuracy of our tests and the history and credibility of our lab in helping them diagnose Lyme and other tick-borne diseases. The Accutix name embodies these qualities and will assist us in building a market leadership position in the tick-borne disease diagnostics market."
The Accutix brand aligns Oxford Immunotec's tick-borne disease offering, which includes over 20 testing options targeting eight tick-borne diseases, under a unified name. The Company will continue to develop new assays for both existing and emerging tick-borne diseases under the Accutix brand.
Tick-borne diseases is the collective name for diseases passed to humans through the bite of an infected tick. As reported by the CDC, the most common tick-borne disease in the United States is Lyme disease, and it is estimated that over 300,000 people are diagnosed with the disease each year. Other tick-borne diseases include Rocky Mountain Spotted Fever, babesiosis, ehrlichiosis, anaplasmosis, Powassan disease, tick-borne relapsing fever and tularemia. According to data maintained by CDC, the incidence of all tick-borne diseases has increased steadily each year and the number of reported cases of Lyme disease more than doubled from 2001 through 2016.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/be24233e-c09e-4c14-beea-21ba6c7ecc4d
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million18.9.2019 13:00:00 CEST | Press release
CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 18 SEPTEMBER 2019 AT 2:00 PM (EEST) Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Cargotec Plc decided on 13 September 2019 to issue two unsecured bonds in the total aggregate nominal amount of EUR 250 million. The first EUR 100 million bond matures on 23 January 2025 and carries a fixed annual interest of 1.250 per cent (ISIN: FI4000399688). The other, a EUR 150 million bond matures on 23 September 2026 and carries a fixed annual interest of 1.625 per cent (ISIN: FI4000399696). Cargotec Plc has today filed an application with Nasdaq Helsinki Ltd for the admission to trading of the bonds on the official list of Nasdaq Helsinki Ltd. Such application is subject to the F
New liquidity providing agreement for Aspo Plc’s share18.9.2019 12:00:00 CEST | Press release
ASPO Plc Stock exchange release September 18, 2019 at 13:00 New liquidity providing agreement for Aspo Plc’s share Aspo Plc and Lago Kapital Ltd have signed a market making agreement in compliance with the Liquidity Providing (LP) requirements issued by Nasdaq Helsinki Ltd. Concurrently, Aspo has terminated its current liquidity providing agreement with Nordea Bank. The current agreement will be in force until Friday October 18, 2019. The new liquidity providing agreement will commence on Monday 21 October, 2019. According to the agreement, Lago Kapital Ltd will provide Aspo’s share with bids and offers so that the maximum spread is 3 per cent, calculated from the bid quotation. Both bid and offer side shall include a number of shares corresponding to the value of at least 3,000 euros. The agreement is in force for a fixed period of 3 months and thereafter until terminated with one month’s term of notice. The market making agreement aims at increasing the share's liquidity and decreasi
Suominen’s financial reporting in 202018.9.2019 12:00:00 CEST | Press release
Suominen Corporation's stock exchange release on September 18, 2019 at 1:00 p.m. EEST Suominen will publish its Financial Statements Release, Half Year Financial Report and two Interim Reports in 2020 as follows: January 29, 2020 - Financial Statements Release for 2019 April 23, 2020 - Interim Report for January-March 2020 August 12, 2020 - Half Year Financial Report for January-June 2020 October 22, 2020 - Interim Report for January-September 2020 The Annual Report for 2019 will be published during the week starting on February 24, 2020 (week 9) at the latest. Suominen's Annual General Meeting is planned to be held on Thursday, March 19, 2020. Suominen's Board of Directors will summon the meeting at a later date. For more information: Emilia Peltola, VP, Communications and IR, tel. +358 10 214 3082 Suominen manufactures nonwovens as roll goods for wipes as well as for medical and hygiene products. The end products made of Suominen’s nonwovens – wet wipes, feminine care products and sw
Nomination Committee for SEB appointed18.9.2019 10:00:00 CEST | Press release
Press release Stockholm 18 September 2019 Nomination Committee for SEB appointed SEB’s Annual General Meeting will be held on Monday, 23 March 2020. The Nomination Committee members are: Petra Hedengran, Investor, Chairman Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, Chairman of the Board, SEB The shareholders having appointed members of the Nomination Committee together represent approximately 36,1 per cent of the voting rights for all shares in the Bank. The SEB Board has appointed Sven Nyman additional member of the Committee. The Nomination Committee will prepare a proposal for Directors etc. to be presented to the Annual General Meeting 2020 for decision. The matters to be dealt with by the Nomination Committee are described on www.sebgroup.com under the heading ‘Annual General Meeting’. A shareholder who would like to submit a proposal to the Nomination Committee can do so by e-mail to firstname.lastname@example.org or by ordinary
Valberedning för SEB utsedd18.9.2019 10:00:00 CEST | Pressemelding
Pressmeddelande Stockholm 18 september 2019 Valberedning för SEB utsedd Årsstämma för Skandinaviska Enskilda Banken kommer att hållas måndagen den 23 mars 2020. Valberedningen består av: Petra Hedengran, Investor, ordförande Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, styrelsens ordförande, SEB De aktieägare som utsett ledamöter till valberedningen, representerar tillsammans cirka 36,1 procent av röstetalet för samtliga aktier i banken. SEB:s styrelse har utsett Sven Nyman att vara adjungerad ledamot av valberedningen. Valberedningen har till uppgift att arbeta fram ett förslag till styrelse m.m. att läggas fram för beslut på årsstämman 2020. De frågor valberedningen ska behandla finns beskrivna på www.sebgroup.com/sv under rubriken ”Årsstämma”. Aktieägare som önskar lämna förslag till valberedningen kan göra det med e-post till email@example.com eller med brev till Skandinaviska Enskilda Banken AB, Valberedningen, Att: Ulf Thornan
MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets18.9.2019 09:00:00 CEST | Press release
DUBLIN, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3 The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. This system is the only commercially available technology in the world to provide protection from highs and lows, and proactively drive increased Time in Range by consistently guiding to the target of 120 mg/dL (6.7mmol/L) throughout the day.4,5 “The Time in Range clinical guidelines recommend that the target of effective diabetes management